Regeneron Acquires 23andMe for $256M in Bankruptcy Sale

Biotech giant Regeneron has agreed to buy 23andMe out of bankruptcy for $256 million, a sharp fall from the consumer DNA-testing company’s $6 billion peak valuation in 2021. Once a leading brand for at-home ancestry kits, 23andMe struggled to profit from its broader vision of personalized healthcare using genetic data.

#Regeneron, #23andMe, #Acquisition, #Biotech, #GeneticData, #StartupFailure, #AnneWojcicki, #PersonalizedMedicine, #DrugDiscovery, #VentureCapital, #HealthcareInnovation, #MergersAndAcquisitions, #DNA